1. Home
  2. PCRX vs PWP Comparison

PCRX vs PWP Comparison

Compare PCRX & PWP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • PCRX
  • PWP
  • Stock Information
  • Founded
  • PCRX 2006
  • PWP 2006
  • Country
  • PCRX United States
  • PWP United States
  • Employees
  • PCRX N/A
  • PWP N/A
  • Industry
  • PCRX Biotechnology: Pharmaceutical Preparations
  • PWP Finance: Consumer Services
  • Sector
  • PCRX Health Care
  • PWP Finance
  • Exchange
  • PCRX Nasdaq
  • PWP Nasdaq
  • Market Cap
  • PCRX 1.2B
  • PWP 1.3B
  • IPO Year
  • PCRX 2011
  • PWP N/A
  • Fundamental
  • Price
  • PCRX $26.86
  • PWP $22.06
  • Analyst Decision
  • PCRX Buy
  • PWP Hold
  • Analyst Count
  • PCRX 6
  • PWP 3
  • Target Price
  • PCRX $30.00
  • PWP $23.67
  • AVG Volume (30 Days)
  • PCRX 592.7K
  • PWP 1.1M
  • Earning Date
  • PCRX 11-05-2025
  • PWP 11-07-2025
  • Dividend Yield
  • PCRX N/A
  • PWP 1.27%
  • EPS Growth
  • PCRX N/A
  • PWP N/A
  • EPS
  • PCRX N/A
  • PWP 0.90
  • Revenue
  • PCRX $705,848,000.00
  • PWP $871,012,000.00
  • Revenue This Year
  • PCRX $7.36
  • PWP $1.99
  • Revenue Next Year
  • PCRX $10.07
  • PWP $25.18
  • P/E Ratio
  • PCRX N/A
  • PWP $24.48
  • Revenue Growth
  • PCRX 2.25
  • PWP 20.01
  • 52 Week Low
  • PCRX $13.04
  • PWP $14.12
  • 52 Week High
  • PCRX $27.64
  • PWP $27.03
  • Technical
  • Relative Strength Index (RSI)
  • PCRX 61.04
  • PWP 52.41
  • Support Level
  • PCRX $25.63
  • PWP $21.67
  • Resistance Level
  • PCRX $27.11
  • PWP $22.75
  • Average True Range (ATR)
  • PCRX 0.96
  • PWP 0.88
  • MACD
  • PCRX -0.05
  • PWP -0.03
  • Stochastic Oscillator
  • PCRX 68.80
  • PWP 62.86

About PCRX Pacira BioSciences Inc.

Pacira BioSciences Inc is a provider of non-opioid pain management and regenerative health solutions dedicated to advancing and improving outcomes for healthcare practitioners and their patients. The company's commercialized non-opioid treatments: EXPAREL a long-acting, local analgesic currently approved for postsurgical pain management; ZILRETTA, an extended-release, intra-articular, corticosteroid injection indicated for the management of osteoarthritis; and iovera, a novel, handheld device for delivering immediate, long-acting, drug-free pain control using precise, controlled doses of cold temperature to a targeted nerve. In addition, it is developing PCRX-201 (enekinragene inzadenovec), a novel gene therapy vector platform for the treatment of osteoarthritis of the knee.

About PWP Perella Weinberg Partners

Perella Weinberg Partners is an independent advisory firm that provides strategic and financial advice to a wide range of clients. The Company's activities as an investment banking advisory firm constitute a single business segment that provides a range of advisory services, including advice related to strategic and financial decisions, mergers and acquisitions execution, shareholder and defense advisory, financing and capital solutions advice with resources focused on restructuring and liability management, capital markets advisory, private capital placement, as well as specialized underwriting and research services for the energy and related industries.

Share on Social Networks: